Milestone Pharmaceuticals Inc. (MIST) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Montreal, QC, カナダ. 現CEOは Joseph G. Oliveto.
MIST を有する IPO日 2019-05-09, 33 名の正社員, に上場 NASDAQ Global Select, 時価総額 $174.35M.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
